title: The effects of osteoclast modifiers on the oral cavity:  a review for prescribers.
abstract: OBJECTIVE
  Osteonecrosis of the jaw associated with therapeutic osteoclast modifiers is a rare but serious event. The consequences of osteonecrosis can be devastating despite current treatment. With the increase in diversity of agents and significant increase in the prevalence of osteoclast modifiers prescribed by oncologists understanding diagnosis and management of osteoclast modifiers-related osteonecrosis of the jaws (OMRONJ) is necessary. The risk of osteonecrosis when osteoclast modifiers are used for management of osteoporosis is much less than osteoclast modifiers used in the oncology setting. A basic understanding of the oral exam and current management will lead to more effective communication and more effective prevention of devastating OMRONJ.
  
  
  RESULTS
  An indistinguishable rate of ONJ seen with new therapeutic agents is becoming apparent and relevant preventive therapy and counseling of the patient is indicated. Currently there is no comprehensive clinical guideline that unifies oncologists and oral health providers in the prevention and management of OMRONJ.
  
  
  CONCLUSIONS
  Communication and proper planning with each patient's provider is the most effective strategy to prevent OMRONJ. A team composed of an oncologist, oral and maxillofacial surgeon and dentist competent in managing this condition is necessary. An understanding of the cause and development of OMRONJ can give the prescriber an improved perspective to communicate with oral health professional colleagues. Current guidelines emphasize the need for dental management prior to the use of osteoclast modifiers for the prevention and management of osteonecrosis of the jaw.
authors.affiliation: Oral and Maxillofacial Surgery Resident, St. Joseph's Regional Medical Center, Paterson, New Jersey, USA.
authors.forename: Matthew S
authors.initials: MS
authors.lastname: Epstein
authors.forename: Joel B
authors.initials: JB
authors.lastname: Epstein
authors.forename: Hillel D
authors.initials: HD
authors.lastname: Ephros
mesh_terms: D059266:Bisphosphonate-Associated Osteonecrosis of the Jaw / Q000209:etiology* / Q000517:prevention & control; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D004164:Diphosphonates / Q000009:adverse effects*; D006801:Humans; D008334:Mandible / Q000187:drug effects*; D010010:Osteoclasts / Q000187:drug effects*; D010024:Osteoporosis / Q000517:prevention & control*; D012306:Risk
chemical_list: D050071:Bone Density Conservation Agents; D004164:Diphosphonates